Is fluorine-18 prostate-specific membrane antigen–1007 positron emission tomography/computed tomography (18F-PSMA-1007 PET/CT) superior to multiparametric magnetic resonance imaging (MRI) for the locoregional primary staging of intermediate-risk and high-risk prostate cancers before treatment? This evidence concerns the gene FOLH1 and prostate cancer.